Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

>

During the first quarter of 2009, we completed our acquisition of Indevus Pharmaceuticals, Inc. and acquired 100% of the outstanding shares of Indevus for a purchase price of $4.50 per share in cash and the non-transferable contractual right to receive up to an additional $3.00 per share in cash payable in the future upon achievement of certain regulatory and sales milestones. The results of operations for Indevus have been included in our consolidated operating results beginning on February 23, 2009.

Conference Call Information

Endo will conduct a conference call with financial analysts to discuss this news release today at 10:30 a.m. ET. Investors and other interested parties may call 866-383-7998 (domestic) or 617-597-5329 (international) and enter code 54725288. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from April 29 at 1:30 p.m. ET until 12:00 a.m. ET on May 6 by dialing 888-286-8010 (domestic) or 617-801-6888 (international), pass code 95260431. A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on May 6. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our GAAP statements of operations to our adjusted statements of operations for each of the three months ended March 31, 2009 and March 31, 2008 (Certain prior period amounts have been reclassified to conform to the current period presentation) (in thousands, except per share data):


    Three Months Ended March 31,      Actual
     2009 (unaudited)                 (GAAP)     Adjustments      Adjusted

    Net sales                  
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... It is that time of year – ... Once again, Evensong Spa at Heidel House ... services at a special $50 rate Oct. 20 through Nov. ... Hotels & Resorts , is the only Wisconsin destination spa ... embrace health and wellness by experiencing affordable spa and wellness ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Use of anesthesia providers to monitor sedation during screening ... from 2003 to 2009 in the United States, with ... not need this service, according to a new RAND ... as $1.1 billion spent annually on anesthesia services for ...
... March 20 (HealthDay News) -- Calculating the difference ... right arms might help predict a patient,s odds of ... Researchers found that people with high blood pressure whose ... higher risk of cardiovascular death over 10 years. ...
... (HealthDay News) -- The northeastern United States may see a significant ... The reason is that oak trees produced relatively few acorns ... years for the acorn crop. But the small crop means trouble ... had a boom in acorns, followed by a boom in mice. ...
... Reporter , TUESDAY, March 20 (HealthDay News) -- ... own stem cells may someday replace or reduce the ... Six months after receiving a kidney transplant, only ... stem cells experienced rejection compared with almost 22 percent ...
... failure and endocrine tumors are among the suspects causing ... relievers in your medicine cabinet be the culprit? ... Sackler Faculty of Medicine and the Sheba Medical Center, ... of hypertension, which is a major risk factor for ...
... March 20 (HealthDay News) -- Seeing a baby,s face triggers ... reward and planning movement, a finding researchers say may indicate ... Researchers observed this pattern in adults who didn,t know the ... "These adults have no children of their own. Yet images ...
Cached Medicine News:Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:Northeast U.S. Should Brace for Spike in Lyme Disease: Expert 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 3Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 4Health News:Pain relievers could be spiking your blood pressure 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2
(Date:9/18/2014)... , Sept. 18, 2014  Iliad Neurosciences, Inc., ... to diagnosing and treating Autism Spectrum Disorders (ASD) announced ... Agreement with The Research Foundation for The State University ... will provide a new biomarker to identify an abnormality ... to ASD. This biomarker is expected to be available ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
... SAN DIEGO, April 13 Researchers from ... today presented findings,showing that adding curcumin or ... preventing the growth of chemo-resistant colon cancer,cells. ... American Association,for Cancer Research (AACR) Annual Meeting ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: